Patents by Inventor Jia-Je LI

Jia-Je LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted prodrug cytosine deaminase fusion carrier and application thereof
    Patent number: 10947270
    Abstract: The present invention provides a targeted prodrug enzyme fusion carrier comprising a targeted molecule and a prodrug enzyme. The targeted prodrug enzyme fusion carrier can effectively identify and bind to tumor cells and tumor-induced tumor angiogenesis. The targeted prodrug enzyme fusion carrier also has a targeted prodrug enzyme fusion protein and a theranostic system utilizing the method of in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: March 16, 2021
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: C. Allen Chang, Hsin-Ell Wang, Jia-Je Li, Shun-Fu Chang, Roy Chen-Chih Wu
  • TARGETED PRODRUG ENZYME FUSION CARRIER AND APPLICATION THEREOF
    Publication number: 20190211057
    Abstract: The present invention provides a targeted prodrug enzyme fusion carrier comprising a targeted molecule and a prodrug enzyme. The targeted prodrug enzyme fusion carrier can effectively identify and bind to tumor cells and tumor-induced tumor angiogenesis. The targeted prodrug enzyme fusion carrier also has a targeted prodrug enzyme fusion protein and a theranostic system utilizing the method of in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors.
    Type: Application
    Filed: January 14, 2019
    Publication date: July 11, 2019
    Inventors: C. Allen Chang, Hsin-Ell Wang, Jia-Je Li, Shun-Fu Chang, Roy Chen-Chih Wu
  • Dual targeting drug carrier and application thereof
    Patent number: 10202432
    Abstract: A dual targeting drug carrier is provided. The dual targeting drug carrier comprises a first targeting molecule and a second targeting molecule, wherein the targeting molecule comprises peptide, protein or antibody. The targeting molecule can bind to specific receptors, proteins, or glycoproteins to recognize the specific tumor cells, tissues, or organs. The dual targeting drug carriers are further conjugated with imaging agents, radioactive molecules (radiopharmaceuticals, isotopes, or chemotherapeutic drugs) or nanoparticles to form a conjugate.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: February 12, 2019
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: Cheng Allen Chang, Keng-Li Lan, Hsin-Ell Wang, Shun-Fu Chang, Jia-Je Li, Pei-Chia Chan
  • DUAL TARGETING DRUG CARRIER AND APPLICATION THEREOF
    Publication number: 20170058011
    Abstract: A dual targeting drug carrier is provided. The dual targeting drug carrier comprises a first targeting molecule and a second targeting molecule, wherein the targeting molecule comprises peptide, protein or antibody. The targeting molecule can bind to specific receptors, proteins, or glycoproteins to recognize the specific tumor cells, tissues, or organs.
    Type: Application
    Filed: November 27, 2015
    Publication date: March 2, 2017
    Inventors: Cheng Allen CHANG, Keng-Li LAN, Hsin-Ell WANG, Shun-Fu CHANG, Jia-Je LI, Pei-Chia CHAN